AP2006003631A0 - Triazole derivatives as vasopressin antagonists - Google Patents

Triazole derivatives as vasopressin antagonists

Info

Publication number
AP2006003631A0
AP2006003631A0 AP2006003631A AP2006003631A AP2006003631A0 AP 2006003631 A0 AP2006003631 A0 AP 2006003631A0 AP 2006003631 A AP2006003631 A AP 2006003631A AP 2006003631 A AP2006003631 A AP 2006003631A AP 2006003631 A0 AP2006003631 A0 AP 2006003631A0
Authority
AP
ARIPO
Prior art keywords
triazole derivatives
vasopressin antagonists
vasopressin
antagonists
triazole
Prior art date
Application number
AP2006003631A
Other versions
AP2331A (en
Inventor
Justin Stephen Bryans
Patrick Stephen Johnson
Lee Richard Roberts
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329693A external-priority patent/GB0329693D0/en
Priority claimed from GB0408789A external-priority patent/GB0408789D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AP2006003631A0 publication Critical patent/AP2006003631A0/en
Application granted granted Critical
Publication of AP2331A publication Critical patent/AP2331A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
AP2006003631A 2003-12-22 2004-12-09 Triazole derivatives as vasopressin antagonists. AP2331A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0329693A GB0329693D0 (en) 2003-12-22 2003-12-22 Compounds useful in therapy
GB0408789A GB0408789D0 (en) 2004-04-20 2004-04-20 Triazole derivatives
PCT/IB2004/004059 WO2005063754A1 (en) 2003-12-22 2004-12-09 Triazole derivatives as vasopressin antagonists

Publications (2)

Publication Number Publication Date
AP2006003631A0 true AP2006003631A0 (en) 2006-06-30
AP2331A AP2331A (en) 2011-12-05

Family

ID=34740750

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003631A AP2331A (en) 2003-12-22 2004-12-09 Triazole derivatives as vasopressin antagonists.

Country Status (25)

Country Link
EP (1) EP1701959A1 (en)
JP (1) JP4698604B2 (en)
KR (1) KR100854872B1 (en)
AP (1) AP2331A (en)
AR (1) AR047340A1 (en)
AU (1) AU2004309164B2 (en)
BR (1) BRPI0417267A (en)
CA (1) CA2551038C (en)
CR (1) CR8481A (en)
DO (1) DOP2004001062A (en)
EA (1) EA010132B1 (en)
EC (1) ECSP066647A (en)
GE (1) GEP20084571B (en)
HK (1) HK1095822A1 (en)
IL (1) IL176349A (en)
IS (1) IS8472A (en)
MA (1) MA28393B1 (en)
NL (1) NL1027833C2 (en)
NO (1) NO20063380L (en)
OA (1) OA13347A (en)
PA (1) PA8620501A1 (en)
PE (1) PE20051051A1 (en)
TW (1) TWI287541B (en)
UY (1) UY28693A1 (en)
WO (1) WO2005063754A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7880009B2 (en) 2004-05-26 2011-02-01 Eisai R&D Management Co., Ltd. Cinnamide compound
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
WO2006034440A2 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003318A (en) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes.
JP5094398B2 (en) 2004-09-20 2012-12-12 ゼノン・ファーマシューティカルズ・インコーポレイテッド Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturases
EP1808432B1 (en) 2004-10-26 2010-02-24 Eisai R&D Management Co., Ltd. Amorphous form of cinnamide compound
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
RU2422442C2 (en) * 2005-07-29 2011-06-27 Ф. Хоффманн-Ля Рош Аг Indole-3-yl-carbonyl-piperidine and piperazine derivatives
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US9090604B2 (en) 2006-07-27 2015-07-28 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
SA07280403B1 (en) 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد Quaternary salt of cinnamide compound
BRPI0720004A2 (en) 2006-12-07 2013-12-17 Hoffmann La Roche SPYROPIPERIDINE DERIVATIVES AS V1A RECEIVER ANTAGONIST
CA2670671A1 (en) * 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
US7501432B2 (en) * 2006-12-22 2009-03-10 Hoffman-La Roche Inc. Spiro-piperidine derivatives
CN101589046B (en) * 2006-12-29 2011-09-21 弗·哈夫曼-拉罗切有限公司 Azaspiro derivatives
PE20081791A1 (en) 2007-02-28 2009-02-07 Eisai Randd Man Co Ltd TWO CYCLIC DERIVATIVES OF OXOMORPHOLIN
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
BRPI0815773A2 (en) 2007-08-31 2019-09-24 Eisai R&D Man Co Ltd compound and medicine.
EP2358202B1 (en) * 2008-11-03 2016-06-15 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
RS54112B1 (en) * 2010-10-01 2015-12-31 Taisho Pharmaceutical Co. Ltd 1,2,4-triazolone derivative
WO2014149819A1 (en) 2013-03-14 2014-09-25 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
WO2015089170A1 (en) 2013-12-12 2015-06-18 Kalyra Pharmaceuticals, Inc. Bicyclic alkyl compounds and synthesis
CN106232567B (en) 2014-03-07 2021-11-02 里科瑞尔姆Ip控股有限责任公司 Propalane derivatives and synthesis
US10308609B2 (en) 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
ES2712886T3 (en) 2014-09-24 2019-05-16 Bayer Pharma AG Derivatives of pyridobenzazepine and pyridobenzazocine that inhibit factor XIa
ES2697902T3 (en) * 2014-11-03 2019-01-29 Bayer Pharma AG Derivatives of phenyltriazole substituted with hydroxyalkyl and its uses
RU2637101C2 (en) * 2016-01-11 2017-11-29 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр вирусологии и микробиологии" (ФГБНУ ФИЦВиМ) Device for determination of aspired dose of aerosols
EP3419626A1 (en) * 2016-02-23 2019-01-02 Servicio Andaluz De Salud Piperazine derivatives as antiviral agents with increased therapeutic activity
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
US20190119251A1 (en) 2016-05-03 2019-04-25 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
WO2017191114A1 (en) 2016-05-03 2017-11-09 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
US10800746B2 (en) 2016-05-03 2020-10-13 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
US10525041B2 (en) 2016-05-03 2020-01-07 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
US10815205B2 (en) 2016-05-03 2020-10-27 Bayer Pharma Aktiengesellschaft Amide-substituted phenyltriazole derivatives and uses thereof
WO2017195703A1 (en) * 2016-05-09 2017-11-16 日本曹達株式会社 Ring-shaped amine compound and pest control agent
EP3529244A1 (en) 2016-10-20 2019-08-28 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof
JP7157769B2 (en) 2017-05-15 2022-10-20 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー analgesic compound
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Prodrugs of substituted triazole derivatives and uses thereof
EP3700896A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
CA3084411A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CR20200176A (en) 2017-10-24 2020-07-24 Bayer Pharma AG Prodrugs of substituted triazole derivatives and uses thereof
US11149023B2 (en) 2017-10-24 2021-10-19 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CA3079771A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
US11173151B2 (en) 2017-10-24 2021-11-16 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
HU231206B1 (en) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepines
TW201938171A (en) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 Tricyclic compounds as vasopressin V1a receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481360A (en) * 1983-08-26 1984-11-06 The Upjohn Company 4H-1,2,4-Triazol-3-yl compounds
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
JP3873746B2 (en) * 2000-05-19 2007-01-24 アステラス製薬株式会社 Triazole derivative

Also Published As

Publication number Publication date
CA2551038A1 (en) 2005-07-14
HK1095822A1 (en) 2007-07-06
OA13347A (en) 2007-04-13
IS8472A (en) 2006-05-18
AP2331A (en) 2011-12-05
IL176349A (en) 2011-11-30
PA8620501A1 (en) 2005-08-04
CA2551038C (en) 2010-04-27
JP4698604B2 (en) 2011-06-08
GEP20084571B (en) 2008-12-25
EA010132B1 (en) 2008-06-30
KR100854872B1 (en) 2008-08-28
TWI287541B (en) 2007-10-01
KR20060101546A (en) 2006-09-25
JP2007515468A (en) 2007-06-14
WO2005063754A1 (en) 2005-07-14
MA28393B1 (en) 2007-01-02
ECSP066647A (en) 2006-10-25
DOP2004001062A (en) 2005-06-30
AU2004309164B2 (en) 2007-11-15
NL1027833A1 (en) 2005-06-23
NL1027833C2 (en) 2006-03-06
AR047340A1 (en) 2006-01-18
BRPI0417267A (en) 2007-04-17
NO20063380L (en) 2006-09-22
EA200600925A1 (en) 2006-12-29
TW200528099A (en) 2005-09-01
UY28693A1 (en) 2005-07-29
AU2004309164A1 (en) 2005-07-14
PE20051051A1 (en) 2005-12-17
CR8481A (en) 2007-12-04
IL176349A0 (en) 2006-10-05
EP1701959A1 (en) 2006-09-20

Similar Documents

Publication Publication Date Title
HK1095822A1 (en) Triazole derivatives as vasopressin antagonists
GB0229618D0 (en) Pyrazole compounds
GB0309637D0 (en) Pyrazole compounds
HK1073304A1 (en) Triazole derivatives as tachykinin receptor antagonists
IL209082A0 (en) Fushed heterocyclic compounds
HK1113927A1 (en) Substituted triazole derivatives as oxytocin antagonists
PL377844A1 (en) Substituted pyrazoles
PL377087A1 (en) Heterocyclic compounds
HK1107977A1 (en) Triazole derivative
HK1085735A1 (en) New benzimidazole derivatives
HK1096824A1 (en) Substituted arylpyrazoles as parasticidal agents
PL377778A1 (en) Pyrazole derivatives
EP1680114A4 (en) Triazole compounds and uses related thereto
ZA200508946B (en) Pyrazole compounds
ZA200508923B (en) Substituted pyrazole compounds
IL173911A0 (en) Imidazole derivatives
EP1689403A4 (en) Heteroaryl-hydrazone compounds
EP1476425A4 (en) Heterocyclic arylsulfonamidobenzylic compounds
IL172821A0 (en) Imidazole derivatives iii
AU2002253456A8 (en) Azole derivatives as antifungal agents
TWI340132B (en) Fungicidal phenoxyphenylhydrazine derivatives
GB0307269D0 (en) Fungicidal compositions
GB0415110D0 (en) Substituted triazole derivatives as oxytocin antagonists
SI1501809T1 (en) Triazole derivatives as tachykinin receptor antagonists
GB0415888D0 (en) Triazole derivatives